查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2011854

干细胞疗法市场：2026-2032年全球市场预测（依治疗方法、细胞来源、技术、给药途径、应用、治疗领域及最终用户划分）

Stem Cell Therapy Market by Therapy Type, Cell Source, Technology, Mode of Administration, Application, Therapeutic Areas, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，干细胞治疗市场价值将达到 50.8 亿美元，到 2026 年将成长至 57.9 亿美元，到 2032 年将达到 133.5 亿美元，复合年增长率为 14.79%。

主要市场统计数据
基准年 2025 50.8亿美元
预计年份：2026年 57.9亿美元
预测年份 2032 133.5亿美元
复合年增长率 (%) 14.79%

我们正在透过创新的干细胞疗法开启医疗保健的新时代，彻底改变患者的治疗效果，并重新定义全球治疗模式。

干细胞疗法正迅速崛起为现代医学中最具前景的新兴领域之一，为修復受损组织、调节免疫反应以及改善多种急慢性疾病的患者预后提供了前所未有的潜力。透过利用这些多功能和多功能细胞固有的再生能力，研究人员和临床医生正在重新定义治疗模式，涵盖从神经退化性疾病到心血管疾病等许多领域。细胞培养技术、基因编辑、生物材料和法规结构方面的进步，推动了干细胞疗法从实验室研究走向实际临床应用。

突破性发现和技术进步如何从根本上改变干细胞疗法的发展和广泛应用？

近年来，干细胞治疗领域经历了变革性的转变，这主要得益于基因编辑、诱导性多功能干细胞中的基因缺陷成为可能，从而为罕见遗传疾病的个人化再生医学铺平了道路。

分析近期美国关税政策对干细胞疗法供应链和研究前景的广泛外溢效应。

美国于2025年初实施的新关税对整个干细胞治疗供应链和研究生态系统产生了一系列连锁反应。关键原料、特殊试剂和高精度设备（其中许多来自海外）成本的上涨，对学术研究机构和商业生产商都造成了影响。因此，采购团队正在重新谈判长期合同，并寻找具备本地生产能力的替代供应商。

透过检验不同的治疗方法、细胞来源、技术、给药途径、应用领域、治疗标靶和最终用户，可以获得关键见解。

要深入了解干细胞治疗市场，必须综合考虑治疗类型、细胞来源、技术、给药途径、应用领域、治疗重点和终端使用者群体之间的相互作用。异体疗法利用供体来源的细胞，由于其生产效率的规模经济优势，正蓬勃发展；而自体疗法儘管个体化治疗成本较高，但因其个性化的安全性，仍然备受青睐。在细胞来源方面，由于造血干细胞和间质干细胞平台的成熟，成体干细胞仍是主流。另一方面，神经前驱细胞因其在中枢神经系统疾病治疗中的应用而日益受到关注。胚胎干细胞在需要多功能的领域中占据了一席之地，而羊水和脐带血等周产期来源的细胞则兼具伦理可接受性和强大的分化潜能。

分析美洲、欧洲、中东和非洲以及亚太地区干细胞治疗市场的主要区域趋势、成长机会和新兴发展。

区域趋势在干细胞疗法研发和商业化过程中发挥着至关重要的作用。在美洲，美国凭藉其稳健的资金筹措环境、完善的临床试验基础设施以及兼顾病患安全和快速核准流程的法规结构，占据主导地位。加拿大正透过对转化研究中心进行策略性资助来巩固其地位，而拉丁美洲国家则开始利用其成本效益高的临床伙伴关係和政府扶持政策来吸引国际奖励。

对世界领先的干细胞治疗研发公司在不断发展的产业格局中的策略定位和创新蓝图检验。

干细胞疗法的竞争格局是由那些在科学创新、监管合规和策略伙伴关係表现卓越的机构所塑造。主要企业正透过将专有技术与强大的生产平台结合，展现其将早期研究推进至临床实验的能力。一些创新者专注于基因编辑的异体细胞株，以应对罕见遗传疾病；而另一些创新者则致力于优化间质干细胞构建体，用于治疗发炎性疾病和组织修復。

旨在加速干细胞治疗领域的创新、优化营运系统和加强合作的实用策略和最佳实践。

产业领导企业应优先投资模组化生产系统，以实现快速规模生产并灵活适应多种细胞类型和治疗标靶。透过采用一次性生物反应器和封闭式系统处理，企业可以最大限度地降低交叉污染风险，并加速不同设施间的技术转移。同时，与试剂供应商和专用设备供应商建立策略合作伙伴关係，可确保优先获得关键投入，并促进合作倡议。

透过结合质性访谈、量化资料分析和专家检验的严谨调查方法，我们确保了对干细胞疗法的扎实了解。

本研究采用融合定性和定量资料的混合方法，对干细胞治疗领域进行了全面概述。初步调查透过对领先生物製药公司高阶主管、监管代表、学术研究人员和契约製造专家进行深度访谈完成。这些访谈使我们深入了解了研发挑战、投资重点和推广应用障碍，包括一些细微差别。

整合关键见解并确定未来路径，以推动全球干细胞应用领域下一代治疗突破。

对技术进步、政策转变和市场动态的全面分析表明，干细胞疗法正处于发展的关键成熟阶段。基因控制和细胞製造技术的突破正在克服先前阻碍规模化和一致性的瓶颈。同时，不断完善的法规和政策正在降低研发过程中的风险，并创造有利于创新的环境。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 干细胞治疗市场依治疗方法划分

  • 顺势疗法
  • 自体疗法

第九章 干细胞疗法市场（依细胞来源划分）

  • 成体干细胞
    • 造血干细胞
    • 间质干细胞
    • 神经干细胞
  • 胚胎干细胞
  • 诱导性多功能干细胞
  • 周产期干细胞
    • 羊水来源干细胞
    • 脐带干细胞

第十章 干细胞疗法市场：依技术划分

  • 生物材料疗法
  • 体外培养
  • 基因编辑技术
  • 利用支架进行治疗

第十一章 依给药途径分類的干细胞治疗市场

  • 关节内
  • 肌肉内部
  • 静脉

第十二章 干细胞治疗市场：依应用领域划分

  • 药物发现与开发
  • 再生医学
  • 组织工程

第十三章 干细胞治疗市场（依治疗领域划分）

  • 心血管疾病
  • 血液学
  • 肌肉骨骼疾病
  • 神经系统疾病
  • 肿瘤学

第十四章 干细胞治疗市场：依最终使用者划分

  • 学术和研究机构
  • 生物製药公司
  • 医院和诊所
  • 干细胞库

第十五章 干细胞治疗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十六章 干细胞治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十七章 干细胞治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十八章 美国干细胞治疗市场

第十九章 中国干细胞治疗市场

第20章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Anterogen Co., Ltd.
  • Astellas Pharma Inc.
  • Beike Biotechnology Co., Ltd.
  • BrainStorm Cell Therapeutics Inc.
  • Bristol-Myers Squibb Company
  • CellProthera SAS
  • Fate Therapeutics, Inc.
  • Gamida Cell Ltd.
  • Garuda Therapeutics
  • Holostem Terapie Avanzate Srl
  • Jasper Therapeutics, Inc.
  • JCR Pharmaceuticals Co., Ltd.
  • Juvena Therapeutics Inc.
  • Kangstem Biotech Co., Ltd.
  • Kite Pharma, Inc. by Gilead Sciences, Inc.
  • Lonza Group AG
  • Medeze Group
  • Merck KGaA
  • Mesoblast Ltd.
  • Novo Nordisk A/S
  • Plasticell
  • ReNeuron Group PLC
  • SQZ Biotechnologies Company by Stemcell Technologies
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.
  • US Stem Cell Inc
  • Umoja Biopharma
  • Vericel Corporation
Product Code: MRR-431752EA49AD

The Stem Cell Therapy Market was valued at USD 5.08 billion in 2025 and is projected to grow to USD 5.79 billion in 2026, with a CAGR of 14.79%, reaching USD 13.35 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.08 billion
Estimated Year [2026] USD 5.79 billion
Forecast Year [2032] USD 13.35 billion
CAGR (%) 14.79%

Pioneering a New Era in Healthcare with Innovative Stem Cell Therapies Revolutionizing Patient Outcomes and Redefining Treatment Paradigms Globally

Stem cell therapy is rapidly emerging as one of the most promising frontiers in modern medicine, offering unprecedented potential to repair damaged tissues, modulate immune responses, and transform patient outcomes across a variety of chronic and acute conditions. By harnessing the innate regenerative capabilities of these pluripotent and multipotent cells, researchers and clinicians are redefining treatment paradigms from neurodegenerative disorders to cardiovascular disease. The convergence of advances in cell culture techniques, gene editing, biomaterials, and regulatory frameworks has elevated stem cell interventions from laboratory curiosities to viable clinical applications.

Against this backdrop, the executive summary provides a concise yet thorough exploration of the forces reshaping the stem cell therapy landscape. It examines groundbreaking technological developments, analyzes the implications of recent policy shifts, and distills critical insights drawn from segmentation and regional dynamics. Emphasis is placed on understanding how emerging cell sources and manufacturing platforms are unlocking new therapeutic avenues, while a spotlight on key stakeholders reveals strategic pathways to leadership.

Drawing on primary interviews with industry experts, secondary literature, and rigorous data validation, this overview equips decision-makers with the knowledge required to navigate complexities and capitalize on opportunities. Whether you are a researcher seeking collaboration, an investor assessing risk, or a corporate strategist charting growth, this executive summary lays the foundation for informed action and sustained innovation.

How Groundbreaking Discoveries and Technological Convergence Are Driving Fundamental Shifts in Stem Cell Therapy Development and Adoption

Recent years have witnessed transformative shifts in the stem cell therapy landscape, driven by breakthroughs in gene editing, induced pluripotent stem cell (iPSC) reprogramming, and automated manufacturing platforms. These innovations are converging to accelerate clinical translation and broaden therapeutic reach. For instance, the refinement of CRISPR-based editing techniques has enabled precise correction of genetic defects in patient-derived cells, opening doors to personalized regenerative interventions for rare inherited disorders.

Parallel advances in scaffold-based delivery systems and biomaterial engineering are enhancing cell viability and targeted engraftment, mitigating historic challenges associated with retention and survival at injury sites. Ex vivo expansion technologies further bolster scalability by allowing the production of high-quality cell populations under controlled conditions, thereby reducing variability and ensuring consistency across batches.

Moreover, public-private partnerships and cross-sector collaborations have fostered shared infrastructure, regulatory guidance, and pooled expertise. These cooperative frameworks are streamlining early-phase clinical trials, facilitating accelerated approval pathways, and de-risking investments. By strategically aligning research institutions, biopharmaceutical firms, and clinical networks, the industry is primed to transition innovative concepts into widespread adoption, marking a pivotal shift from proof-of-concept studies to robust, scalable therapeutic programs.

Analyzing the Broad Ripple Effects of Recent United States Tariff Policies on the Stem Cell Therapy Supply Chain and Research Outlook

The introduction of new tariffs by the United States in early 2025 has triggered a series of reverberations throughout the stem cell therapy supply chain and research ecosystem. Key raw materials, specialized reagents, and high-precision instrumentation-many of which are sourced internationally-have seen input costs rise, affecting both academic laboratories and commercial manufacturers. As a result, procurement teams are renegotiating long-term contracts and exploring alternative suppliers with regional manufacturing capabilities.

In addition to elevated costs, extended customs clearance times have disrupted just-in-time inventory models, compelling facilities to build buffer stocks and adapt warehouse management systems. This shift has inadvertently underscored the value of strategic localization, with some organizations electing to repatriate critical processes closer to end-markets to mitigate tariff exposure.

On the research front, regulatory bodies have shown a willingness to accommodate conditional approvals and rolling submissions in response to supply chain pressures. This flexibility has enabled certain clinical programs to maintain momentum, even as budgetary allocations are rebalanced to absorb incremental import duties. Looking ahead, stakeholders are reevaluating risk management frameworks, prioritizing vertical integration, and forging cross-border alliances to preserve operational continuity and capitalize on evolving policy landscapes.

Unlocking Critical Insights by Examining Diverse Therapy Types, Cell Sources, Technologies, Administration Modes, Applications, Therapeutic Targets, and End Users

Insight into the stem cell therapy market emerges most clearly when one considers the interplay of therapy types, cell sources, technologies, administration routes, application areas, therapeutic focus, and end-user segments. Allogeneic therapies, which leverage donor-derived cells, are gaining momentum thanks to scalable manufacturing efficiencies, whereas autologous approaches continue to appeal for their personalized safety profile despite higher individualized processing costs. From a sourcing perspective, adult stem cells remain a mainstay thanks to established hematopoietic and mesenchymal platforms, while neural precursors are advancing for central nervous system indications. Embryonic stem cells are carving niches where pluripotency is essential, complemented by perinatal populations such as amniotic fluid and umbilical cord cells that combine ethical acceptability with robust differentiation capacity.

On the technological front, biomaterial-enhanced constructs and scaffold systems are optimizing cell delivery and retention. Gene-edited technologies are refining therapeutic specificity by eliminating immunogenic markers and correcting pathogenic variants. Ex vivo expansion solutions are seamlessly integrated with automated bioreactors to deliver consistent cell quality at scale. In parallel, the choice of administration route-ranging from intra-articular injections for musculoskeletal applications to intravenous infusions for systemic disorders-is being tailored to both clinical objectives and patient comfort.

Applications in drug discovery are utilizing stem cell-derived models to predict toxicity and efficacy, while regenerative medicine platforms target tissue restoration across cardiovascular, neurological, and musculoskeletal domains. Tissue engineering collaborations are producing hybrid constructs for organ repair. Across these domains, academic and research institutes fuel basic science discoveries, biopharmaceutical companies shepherd translational programs, hospitals and clinics drive clinical trial enrollment and real-world evidence collection, and specialized stem cell banks underpin both supply reliability and quality assurance.

Mapping Key Regional Dynamics, Growth Opportunities, and Emerging Trends Across the Americas, Europe Middle East Africa, and Asia-Pacific Stem Cell Therapy Markets

Regional dynamics play a decisive role in shaping the trajectory of stem cell therapy development and commercialization. In the Americas, the United States leads with a robust funding environment, established clinical trial infrastructure, and a regulatory framework that balances patient safety with accelerated pathways. Canada is bolstering its position through strategic funding of translational research hubs, while Latin American countries are beginning to attract international partnerships by leveraging cost-effective clinical networks and supportive government incentives.

Within Europe, Middle East, and Africa, Europe's landscape is characterized by harmonized regulatory guidelines and a vibrant community of centers of excellence. Western European nations are driving first-in-human studies, while emerging markets in the Middle East and North Africa are investing in biomanufacturing capacity and public-private innovation clusters. Collaborative frameworks between the European Medicines Agency and regional authorities are laying the foundation for unified compassionate use programs and standardized quality controls.

In the Asia-Pacific arena, nations such as Japan and South Korea have established favorable cell therapy roadmaps, including conditional approvals and reimbursement models that mitigate development risk. China's expansive clinical trial footprint and growing network of contract development and manufacturing organizations present both opportunities and competitive pressures. India, Australia, and Southeast Asian nations are accelerating research through government grants and cross-border research partnerships, creating a diverse ecosystem that spans early-stage discovery to late-stage commercialization.

Examining Strategic Positioning and Innovation Roadmaps of Leading Global Developers in the Evolving Stem Cell Therapy Industry Landscape

The competitive landscape of stem cell therapy is defined by organizations that excel in scientific innovation, regulatory navigation, and strategic partnerships. Leading companies have demonstrated the capacity to advance early-stage research into pivotal trials by integrating proprietary technologies with robust manufacturing platforms. Some innovators are focusing on gene-edited allogeneic cell lines to address rare genetic disorders, while others are optimizing mesenchymal stem cell constructs for inflammatory conditions and tissue repair.

Strategic alliances between biotech firms and large pharmaceutical companies are accelerating late-stage clinical development, leveraging established distribution channels and deep reimbursement expertise. Contract development and manufacturing organizations are stepping into the spotlight by offering end-to-end solutions, from cell banking through fill-and-finish operations, thereby de-risking capital expenditure for small to mid-sized developers.

In parallel, a number of academic spin-off enterprises are carving out niches by translating novel differentiation protocols or biomaterial formulations into early-phase trials. Venture capital and strategic corporate investors continue to back these high-potential ventures, focusing on pipelines that span oncology to neurological diseases. Collectively, these stakeholders are reshaping the sector by aligning scientific ambition with commercial pragmatism, setting new benchmarks for efficacy, safety, and scalability.

Implementable Strategies and Best Practices Designed to Accelerate Innovation, Optimize Operational Frameworks, and Enhance Collaboration in Stem Cell Therapy

Industry leaders should prioritize investment in modular manufacturing systems that allow rapid scale-up and flexible adaptation to multiple cell types and therapeutic targets. By adopting single-use bioreactors and closed-system processing, organizations can minimize cross-contamination risk and accelerate technology transfer across facilities. Concurrently, forging strategic alliances with reagent suppliers and specialized equipment vendors will secure preferential access to critical inputs and foster co-development initiatives.

To navigate evolving regulatory landscapes, companies must implement proactive engagement strategies with health authorities, submitting data packages that emphasize process validation and real-world evidence. Leveraging adaptive trial designs can shorten timelines while preserving rigorous safety and efficacy standards. Building global trial networks and harmonizing clinical protocols will also reduce duplicate efforts and streamline patient recruitment.

Furthermore, embracing digital health solutions-such as remote monitoring, electronic patient-reported outcomes, and blockchain-enabled supply chain tracking-will enhance transparency, patient adherence, and quality control. Finally, cultivating cross-disciplinary talent through targeted training programs and academic collaborations will ensure the workforce remains adept at integrating emerging science with commercial imperatives, laying the groundwork for sustainable growth.

Rigorous Methodological Approach Combining Qualitative Interviews, Quantitative Data Analysis, and Expert Validation to Ensure Robust Stem Cell Therapy Insights

This research is founded upon a mixed-methods approach that integrates qualitative and quantitative data to produce a holistic view of the stem cell therapy sector. Primary research was conducted through in-depth interviews with executives from leading biopharmaceutical firms, regulatory agency representatives, academic investigators, and contract manufacturing experts. These discussions provided nuanced understanding of development challenges, investment priorities, and adoption barriers.

Secondary research encompassed a thorough review of peer-reviewed publications, patent filings, government policy documents, and public company disclosures. Data points were triangulated to verify consistency and identify divergent trends across sources. Proprietary databases tracking clinical trial activities, technology licensing agreements, and capital investment flows were also leveraged to ensure comprehensive coverage.

All quantitative inputs underwent rigorous validation through cross-referencing with expert feedback. Key assumptions were stress-tested under multiple scenarios to assess impact on operational and regulatory variables. The resulting framework ensures that insights are both robust and actionable, offering stakeholders a reliable foundation for strategic decision-making in this rapidly evolving domain.

Synthesizing Critical Discoveries and Identifying Future Pathways to Propel the Next Generation of Therapeutic Breakthroughs in Stem Cell Applications Worldwide

The synthesis of technological advances, policy shifts, and market dynamics underscores a pivotal moment for the maturation of stem cell therapies. Breakthroughs in gene regulation and cell manufacturing are converging to overcome historical bottlenecks in scale and consistency. At the same time, evolving regulatory policies and strategic collaborations are de-risking development pathways and fostering an environment conducive to innovation.

Segmentation insights reveal that no single approach will dominate; rather, a diversified portfolio encompassing allogeneic and autologous products, multiple cell sources, and varied delivery platforms will characterize the next phase of growth. Regional analyses highlight that global market penetration will depend on tailoring strategies to local regulatory, reimbursement, and infrastructure conditions.

Ultimately, success in this arena will hinge on aligning scientific rigor with commercial agility, forging partnerships across the ecosystem, and maintaining an unwavering focus on patient-centered outcomes. By synthesizing these critical discoveries and identifying future pathways, stakeholders are better positioned to usher in the next generation of therapeutic breakthroughs and deliver transformative care to patients around the world.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Stem Cell Therapy Market, by Therapy Type

  • 8.1. Allogeneic Therapy
  • 8.2. Autologous Therapy

9. Stem Cell Therapy Market, by Cell Source

  • 9.1. Adult Stem Cells
    • 9.1.1. Hematopoietic Stem Cells
    • 9.1.2. Mesenchymal Stem Cells
    • 9.1.3. Neural Stem Cells
  • 9.2. Embryonic Stem Cells
  • 9.3. Induced Pluripotent Stem Cells
  • 9.4. Perinatal Stem Cells
    • 9.4.1. Amniotic Fluid Stem Cells
    • 9.4.2. Umbilical Cord Stem Cells

10. Stem Cell Therapy Market, by Technology

  • 10.1. Biomaterial Based Therapy
  • 10.2. Ex Vivo Expansion
  • 10.3. Gene Edited Technologies
  • 10.4. Scaffold Based Therapy

11. Stem Cell Therapy Market, by Mode of Administration

  • 11.1. Intra-articular
  • 11.2. Intramuscular
  • 11.3. Intravenous

12. Stem Cell Therapy Market, by Application

  • 12.1. Drug Discovery & Development
  • 12.2. Regenerative Medicine
  • 12.3. Tissue Engineering

13. Stem Cell Therapy Market, by Therapeutic Areas

  • 13.1. Cardiovascular Diseases
  • 13.2. Hematology
  • 13.3. Musculoskeletal Disorders
  • 13.4. Neurological Disorders
  • 13.5. Oncology

14. Stem Cell Therapy Market, by End User

  • 14.1. Academic & Research Institutes
  • 14.2. Biopharmaceutical Companies
  • 14.3. Hospitals & Clinics
  • 14.4. Stem Cell Banks

15. Stem Cell Therapy Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Stem Cell Therapy Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Stem Cell Therapy Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Stem Cell Therapy Market

19. China Stem Cell Therapy Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. Anterogen Co., Ltd.
  • 20.6. Astellas Pharma Inc.
  • 20.7. Beike Biotechnology Co., Ltd.
  • 20.8. BrainStorm Cell Therapeutics Inc.
  • 20.9. Bristol-Myers Squibb Company
  • 20.10. CellProthera SAS
  • 20.11. Fate Therapeutics, Inc.
  • 20.12. Gamida Cell Ltd.
  • 20.13. Garuda Therapeutics
  • 20.14. Holostem Terapie Avanzate S.r.l.
  • 20.15. Jasper Therapeutics, Inc.
  • 20.16. JCR Pharmaceuticals Co., Ltd.
  • 20.17. Juvena Therapeutics Inc.
  • 20.18. Kangstem Biotech Co., Ltd.
  • 20.19. Kite Pharma, Inc. by Gilead Sciences, Inc.
  • 20.20. Lonza Group AG
  • 20.21. Medeze Group
  • 20.22. Merck KGaA
  • 20.23. Mesoblast Ltd.
  • 20.24. Novo Nordisk A/S
  • 20.25. Plasticell
  • 20.26. ReNeuron Group PLC
  • 20.27. SQZ Biotechnologies Company by Stemcell Technologies
  • 20.28. Takara Bio Inc.
  • 20.29. Thermo Fisher Scientific Inc.
  • 20.30. U.S. Stem Cell Inc
  • 20.31. Umoja Biopharma
  • 20.32. Vericel Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL STEM CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL STEM CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL STEM CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL STEM CELL THERAPY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL STEM CELL THERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL STEM CELL THERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES STEM CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA STEM CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL STEM CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ALLOGENEIC THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ALLOGENEIC THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ALLOGENEIC THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL STEM CELL THERAPY MARKET SIZE, BY AUTOLOGOUS THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL STEM CELL THERAPY MARKET SIZE, BY AUTOLOGOUS THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL STEM CELL THERAPY MARKET SIZE, BY AUTOLOGOUS THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL STEM CELL THERAPY MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL STEM CELL THERAPY MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL STEM CELL THERAPY MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL STEM CELL THERAPY MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL STEM CELL THERAPY MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL STEM CELL THERAPY MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL STEM CELL THERAPY MARKET SIZE, BY NEURAL STEM CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL STEM CELL THERAPY MARKET SIZE, BY NEURAL STEM CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL STEM CELL THERAPY MARKET SIZE, BY NEURAL STEM CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL STEM CELL THERAPY MARKET SIZE, BY EMBRYONIC STEM CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL STEM CELL THERAPY MARKET SIZE, BY EMBRYONIC STEM CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL STEM CELL THERAPY MARKET SIZE, BY EMBRYONIC STEM CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL STEM CELL THERAPY MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL STEM CELL THERAPY MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL STEM CELL THERAPY MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL STEM CELL THERAPY MARKET SIZE, BY AMNIOTIC FLUID STEM CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL STEM CELL THERAPY MARKET SIZE, BY AMNIOTIC FLUID STEM CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL STEM CELL THERAPY MARKET SIZE, BY AMNIOTIC FLUID STEM CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL STEM CELL THERAPY MARKET SIZE, BY UMBILICAL CORD STEM CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL STEM CELL THERAPY MARKET SIZE, BY UMBILICAL CORD STEM CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL STEM CELL THERAPY MARKET SIZE, BY UMBILICAL CORD STEM CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL STEM CELL THERAPY MARKET SIZE, BY BIOMATERIAL BASED THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL STEM CELL THERAPY MARKET SIZE, BY BIOMATERIAL BASED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL STEM CELL THERAPY MARKET SIZE, BY BIOMATERIAL BASED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL STEM CELL THERAPY MARKET SIZE, BY EX VIVO EXPANSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL STEM CELL THERAPY MARKET SIZE, BY EX VIVO EXPANSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL STEM CELL THERAPY MARKET SIZE, BY EX VIVO EXPANSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL STEM CELL THERAPY MARKET SIZE, BY GENE EDITED TECHNOLOGIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL STEM CELL THERAPY MARKET SIZE, BY GENE EDITED TECHNOLOGIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL STEM CELL THERAPY MARKET SIZE, BY GENE EDITED TECHNOLOGIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL STEM CELL THERAPY MARKET SIZE, BY SCAFFOLD BASED THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL STEM CELL THERAPY MARKET SIZE, BY SCAFFOLD BASED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL STEM CELL THERAPY MARKET SIZE, BY SCAFFOLD BASED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL STEM CELL THERAPY MARKET SIZE, BY INTRA-ARTICULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL STEM CELL THERAPY MARKET SIZE, BY INTRA-ARTICULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL STEM CELL THERAPY MARKET SIZE, BY INTRA-ARTICULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL STEM CELL THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL STEM CELL THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL STEM CELL THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL STEM CELL THERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL STEM CELL THERAPY MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL STEM CELL THERAPY MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL STEM CELL THERAPY MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL STEM CELL THERAPY MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL STEM CELL THERAPY MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL STEM CELL THERAPY MARKET SIZE, BY REGENERATIVE MEDICINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL STEM CELL THERAPY MARKET SIZE, BY REGENERATIVE MEDICINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL STEM CELL THERAPY MARKET SIZE, BY REGENERATIVE MEDICINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL STEM CELL THERAPY MARKET SIZE, BY TISSUE ENGINEERING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL STEM CELL THERAPY MARKET SIZE, BY TISSUE ENGINEERING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL STEM CELL THERAPY MARKET SIZE, BY TISSUE ENGINEERING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL STEM CELL THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL STEM CELL THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL STEM CELL THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL STEM CELL THERAPY MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL STEM CELL THERAPY MARKET SIZE, BY HEMATOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL STEM CELL THERAPY MARKET SIZE, BY HEMATOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL STEM CELL THERAPY MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL STEM CELL THERAPY MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL STEM CELL THERAPY MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL STEM CELL THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL STEM CELL THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL STEM CELL THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL STEM CELL THERAPY MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL STEM CELL THERAPY MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL STEM CELL THERAPY MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL STEM CELL THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL STEM CELL THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL STEM CELL THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL STEM CELL THERAPY MARKET SIZE, BY STEM CELL BANKS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL STEM CELL THERAPY MARKET SIZE, BY STEM CELL BANKS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL STEM CELL THERAPY MARKET SIZE, BY STEM CELL BANKS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL STEM CELL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS STEM CELL THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL STEM CELL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. GCC STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. GCC STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. GCC STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 196. GCC STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 197. GCC STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 198. GCC STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 199. GCC STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 200. GCC STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 201. GCC STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 202. GCC STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. G7 STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 224. G7 STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. G7 STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 226. G7 STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 227. G7 STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 228. G7 STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 229. G7 STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 230. G7 STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 231. G7 STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 232. G7 STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. NATO STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 234. NATO STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. NATO STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 236. NATO STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 237. NATO STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 238. NATO STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 239. NATO STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 240. NATO STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 241. NATO STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 242. NATO STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. GLOBAL STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES STEM CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA STEM CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 255. CHINA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. CHINA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 260. CHINA STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 263. CHINA STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)